852 Modified-epitope-based vaccine (OSE2101) combined with anti-PD-1/IL-7v bispecific antibody sustains long-lasting tumor specific antigen memory T cell response in vivo

• Caroline Mary,
• Géraldine Teppaz,
• Ariane Desselle,
• Virginie Thépénier,
• Nicolas Poirier,
• Aurore morello,
• Margaux Seite,
• Justine Durand,
• Cecile Batty,
• Belarif Lyssia,
• Julien Taurelle,
• Berangere Vasseur,
• Thomas Vandewalle,
• Laurie Cordonnier

Affiliations

Caroline Mary

OSE Immunotherapeutics, Nantes, France

Géraldine Teppaz

OSE Immunotherapeutics, Nantes, Loire-Atlantique, France

Ariane Desselle

OSE Immunotherapeutics, Nantes, Loire-Atlantique, France

Virginie Thépénier

OSE Immunotherapeutics, Nantes, Loire-Atlantique, France

Nicolas Poirier

OSE Immunotherapeutics, Nantes, Loire-Atlantique, France

Aurore morello

OSE Immunotherapeutics, Nantes, France

Margaux Seite

OSE Immunotherapeutics, Nantes, Loire-Atlantique, France

Justine Durand

OSE Immunotherapeutics, Nantes, Loire-Atlantique, France

Cecile Batty

OSE Immunotherapeutics, Nantes, Loire-Atlantique, France

Belarif Lyssia

OSE Immunotherapeutics, Nantes, France

Julien Taurelle

OSE Immunotherapeutics, Nantes, France

Berangere Vasseur

OSE Immunotherapeutics, Nantes, France

Thomas Vandewalle

OSE Immunotherapeutics, Nantes, France

Laurie Cordonnier

OSE Immunotherapeutics, Nantes, France